2029 Immunization Vaccines 
European Pharmaceutical Review
SEPTEMBER 1, 2023
The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. percent share by 2029, the research has shown. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.
European Pharmaceutical Review
MAY 7, 2024
percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. by 2029 appeared first on European Pharmaceutical Review. The market is anticipated to value $1139.4
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 30, 2022
It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.
Express Pharma
AUGUST 31, 2023
The global market for mRNA-based oncology therapies is expected to reach a record-breaking $2 billion by 2029. per cent share by 2029, according to GlobalData. If successful, this trial will mark the first time an mRNA cancer vaccine and an immune checkpoint inhibitor have shown improved recurrence-free survival rates.
Express Pharma
NOVEMBER 3, 2023
Pfizer has recently announced the FDA approval of Penbraya, the first and only pentavalent vaccine for coverage against the most common serogroups causing meningococcal disease in people aged 10 to 25 years. Penbraya has the potential to help simplify complex vaccination schedules by providing broader serogroup coverage with fewer doses.”
Expert insights. Personalized for you.
110 
Let's personalize your content